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As we are living in a Covid-19 spreading environment, people can 
never feel more important and vulnerable the health itself is. 
Naturally, we feel interested to do an equity research on a 
healthcare company. Coincidently, the news that an HPV nine-
valent vaccine was finally available in mainland China and the 
exporter —— GSK arose our interest. Thus, we did a brief 
investigation into it and found this company is appropriate to be 
our research target.  
 
Our work industry and company overview, macroeconomics 
environment, past analysis, forecast and valuation. It is based on 
the corporate valuation, financial statement analysis and financial 
report knowledge that we learned at Novasbe.  
 
We started from analyzing the company and its macro 
environment, we did a forecast on its revenue, income statement, 
balance sheet and cash flow statement. Note that instead of 
choosing GDP and population as drivers, we decided to not apply 
any drives because it’s more reasonable to forecast its revenue 
based on its products and patent. Then, A APV model has been 
applied to deal with the valuation. 
 
We got a brief conclusion that GSK’s stock is undervalued and it’s 
worth to buy GSK stocks with an expected return of 23.0% 
 
After completing this study, we could know better not only our 
target company GSK but also other pharma companies. Our equity 
research can serve as a good guideline for investors who want to 
know about healthcare stocks. 
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This report is part of the GSK report (annexed) and should be read has an integral part of 
it. 
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Investment and Strategy 
To strengthen GSK’s business, it increased investment in R&D and in 2019, it had 
39 medicines and 15 vaccines in the pipeline, also three major approvals, eight 
regulatory submissions, six positive read-outs from pivotal studies. Moreover, it 
progressed four new assets into pivotal studies1. However, in comparison with its 
peers, GSK has the lowest number of medicines in the pipeline. GSK’s late-stage 
pipeline is still thin versus some of its peers, for instance, Novartis is holding 20 
medicine in third phase versus GSK’s 13 product (including vaccines). Among 
interesting prospects in GSK’s pipeline is Zejula, which was approved as first-line 
monotherapy in April by FDA and have the potential to reach blockbuster (1 billion) 
status. Other prospects that have been submitted for FDA approval include 
respiratory syncytial virus and Chronic Obstructive Pulmonary Disease (COPD) 
vaccines, oncology asset Belantamab Mafodotin, HIV drug Cabotegravir, and 
Bintrafusp Alpha (developed under alliance with Merck KGaA). We expect GSK 
will continue looking for deals that could further strengthen its pipeline. (See below 
Forecast section for more information). 
To understand better GSK’s R&D investment, we run an analysis of a ten-year 
RORC2 among GSK and its competitors (Appendix 1). In 2019, the GSK’s RORC 
(with a lag of 3 year) is 6,53 which means, for each pound invested in R&D, after 
3 year, the company earned £6.53 in gross profit. GSK’s RORC climbed gradually 
over the last ten years, in which it exceeded the average RORC (around 5) among 
pharma companies since 2017. It reflects that GSK’s R&D investment is relatively 
effective among its peers. The high value of RORC of 6.53 in 2019 indicates that 
GSK has spent wisely in terms of research and development and is obtained the 
rewards from its efforts. It’s interesting to note that Bayer, Pfizer and Johnson & 
Johnson, similar to GSK, who develop not only pharmaceuticals but also own 
Consumer Healthcare unit, have a high RORC compared to its sole pharma peers. 
This is in accordance with the fact that drugs cost more R&D expenditure than 
Consumer Healthcare products. 
In Q1 2020, GSK initiated a two-year program3 to prepare for the separation of 
the company into two entities: New GSK4, a biopharma focusing on science related 
to the immune system, application of genetics and advanced technologies 
development; and a New Consumer Healthcare company which will be aimed at 
 
1 A pivotal study is a clinical study that intends to provide the ultimate evidence and data that the FDA uses to decide 
whether or not to approve a potential new medicine. 
2 RORC = Gross Profit (t)/ R&D cost (t-n), n = years of lag 
3 This program initiated in 2020 and it is expected to be finished in the end of 2021. 
4 This company will focus on pharmaceutical and vaccines products. 
Source: Annual Reports 
Source: Analyst Graph 
Two new companies to set 
competitive and a different cost 
base. 
 
Source: Analyst Graph 
 
consumer healthcare products. The program targets cost savings through 
organization improvement and deleverage the whole group through IPO of New 
Consumer Healthcare company. (Please refer to Alternative Scenario regarding 
this saving program). 
The Joint Venture with Pfizer Consumer Healthcare business was completed 
on 31 July 2019, which GSK holds a 68% stake and has a full operational control 
and management. According to Pfizer publishment, this investment makes the joint 
venture to occupy the first position in the US market and second position in China 
– the two biggest OTC markets in the world. In order to analyze the JV’s impact on 
the profit, we made following assumption: the cost of sale of each unit would be 
equal to the percentage of its contribution to the revenue. With this assumption, it 
was calculated that the gross profit margin in Q3 2019 is 17.61% comparing to 
18.67% in Q3 2020. The gross profit margin of Consumer Healthcare unit has gone 
up by 1%, verifying a slight margin improvement in the first year after JV formation.   
The global oncology drugs market was $97bn in 2017 and is estimated to reach at 
$176bn by 2025, with a CAGR of 7.6% from 2018 to 2025. The high growth 
potential in developing countries, increasing number of pipeline products, and rise 
in demand for personalized medicines are main drivers for the market players5. To 
strengthen the pharmaceutical pipeline, especially in oncology sector, GSK began 
to acquire 100% of Tesaro Inc for $5.1bn in cash from the end of 2018 and it was 
completed during 2019. Tesaro is acquired by $75 a share, a 110% premium to 
Tesaro’s 30-day volume-weighted average price. According to a report of 
Bloomberg the key product Zejula would not bring much profit to GSK, since its 
main competitor Lynparza has generated formidable data in recent clinical trials. 
However, in April of 2020, the FDA green-lighted Zejula as a first-line maintenance 
therapy for all women, regardless of BRCA mutation status.6  In our point of view, 
Tesaro acquisition is a good deal for GSK, although in the short term, only revenue 
generated by Zejula was consolidated in the  total revenue (1% of total revenue in 
2019), in the long term, Tesaro brings 15 new medicines in the pipelines, enabling 
GSK to rebuild its oncology commercial infrastructure and developing its own 
immune-oncology combination therapies internally, reducing its dependence with 
external partners. Tesaro has the most advanced pipeline product which is in the 
same immune-boosting class as Keytruda, arguably the only group of cancer 
drugs more competitive than PARPs7. Moreover, we believe the acquisition of 
Tesaro is rational as GSK once sold its oncology sector in 2014 to Novartis but 
returned to cancer sector two years later with absorption of small cancer drugs to 
 
5 Market Analysis - (2019) Volume 7 
6 FiercePharma platform: https://www.fiercepharma.com/pharma/glaxosmithkline-s-zejula-jumps-ahead-lynparza-all-
comers-ovarian-cancer-nod 
7 Poly (ADP-ribose) Polymerase is a family of proteins involved in a number of cellular processes such as DNA repair, 
genomic stability, and programmed cell death. 
Acquisition of Tesaro to 
return to the battle against 
cancer. 
 
Source: Analyst Graph 
Existed from the crowded 
“first generation” market 
and entered the potential 
immune-oncology market 
 
its portfolio. According to Citigroup, GSK tried to get rid of its “last generation” 
products and focus on “Transformational” cancer drugs that are either first-in-
class or highly differentiated from rivals. 
Due to the lack of technologies to counter T cell “exhaustion” and to enhance the 
activity and specificity of cell therapies in solid tumor cancer, the firm announced 
a five-year collaboration (2020-2024) with Lyell Immunopharma, a cellular therapy 
company. These investments show a positive expectation by GSK regarding 
oncology sector, however, $5bn of debt to support the acquisition of Tesaro and 
investments to further develop its asset as well as investment in the oncology 
commercial infrastructure would lead to a contradiction in GSK’s operating margin 
in Pharmaceutical Unit – in addition of the continued lower revenue from Advair in 
total revenue. 
GSK divested its Horlicks8 business to Hindustan Unilever Limited (HUL), in return 
of 5.7% equity stake in HUL and approximately £0.4bn in cash on 1 April of 2020. 
During May 2020, with the appreciation of the shares value of HUL, GSK sold its 
5.7% equity stake for approximately £2.8bn. This price is in line with GSK’s 
expectation (approximately £3.1bn) since they received £0.4bn in cash previously. 
According to the Q3-20 report, this profit was allocated for debt repayment9. 
To maintain its global vaccines market, GSK puts its two key assets: Shingrix and 
Bexsero focusing on the US and China, two largest vaccines markets in the world. 
During the last four years, there are huge increases in vaccines’ sales in these two 
markets. For instance, the total sales of vaccines in China has increased from 
¥24bn in 2016 to ¥42.5bn in 2019 and the US has climbed to $16.6bn in 2019 from 
$12.7bn in 2016. In 2019, GSK received regulatory approval for Shingrix in China 
where the firm planned to have a phased launch to ensure its continuity of supply. 
On the other hand, to further grow Bexsero, which already had a 70% share of the 
global meningitis B vaccines market in 2019, the firm will focus on EU and US 
market. As the competitors in EU only offer adolescent protection, GSK can be 
benefitted in offering infant products. Furthermore, the firm is developing an MMR 
(Measles, Mumps and Rubella) vaccine and a PCV-free (Porcine Circovirus) 
formulation rotavirus vaccine specifically for the US market. 
In the end GSK is also working on vaccine for the Covid-19. The firm collaborated 
with Sanofi to support the COVAX Facility to make their vaccine adjuvant 
technology (AS03) available for the development of an effective vaccine and global 
response to the coronavirus epidemic. However, due to the unsuccessful 
development of vaccines in immune response in older adults, they announced to 
 
8 Horlicks is a nutrition drinks product that was in the Healthcare division of GSK. 
9 £3.3 billion decreased in net debt which including shares revenue in the Horlicks Unilever of £2.7 billion and £0.6 billion 
of other assets. 
Source: Statista 
Five year of collaboration 
with Lyell to enhance its 
cell therapies 
 
The divestment of the 
Indian Horlicks business 
for the debt payment 
delay its vaccines supply to the end of 2021. During November 2020, GSK and 
Medicago, another biopharmaceutical firm, announced their positive result of 
adjuvanted Covid19 vaccines in phase I and started the phase II/III clinical trials. 
Nevertheless, even with the success of vaccines’ development by GSK and 
Medicago, there are already 2 vaccines in the market (Pfizer and Moderna). 
According to the Eikon platform, when there is announcement of success of Covid-
19 vaccines, Pfizer’s share price has increased by 16% and Moderna increased 
by 46%. However, after 1 week, their price dropped back to their former level 
(Pfizer with $37.84 and Moderna with $111.40). In the beginning of December, 
Johnson&Johnson also announced its vaccines’ success in the third phase. Its 
share price increased by 7% to $154.51. Therefore, in our point of view, even with 
the success of Covid-19 vaccines by GSK, its impact on GSK share price would 
be diminutive (1% to 5% of increase), since it would only be available in the end of 
2021. 
Macroeconomic Environment 
Brexit: The consequence of Brexit is still an uncertainty for the firm. It affected its 
supply chain and the product quality, however, GSK believed that Brexit would 
not have a material impact on its business. For instance, GSK has been 
engaging with Governments in both the UK and EU27, as well as Brussels 
institutions, to discuss their preparations and their ambitions for the new UK/EU 
relationship (Including the taxes issues and regulations). Furthermore, GSK has 
prepared currently a new post Brexit operating model. The firm planned the 
retesting and certification of medicines and consumer products in Europe where 
required and they have completed relevant marketing authorization transfers, 
updated packaging and secured additional warehousing for products. 
In the end of December 2020, the deal is completed. There is no huge change in 
trade policies. The agreement establishes zero tariffs or quotas on trade between 
UK and the EU. Regarding Pharmaceutical products, There is annex which aims 
to facilitate availability of medicines, promote public health and protect high levels 
of consumer and environmental protection in respect of medicinal products. It 
provides mutual recognition of Good Manufacturing Practice (GMP) inspections 
and certificates, Thus, manufacturing facilities do not need to undergo separate 
UK and EU inspections, as well as ongoing co-operation. 
Exchange rate: According to the Yahoo finance platform, the lowest exchange 
rate of GBP to USD during the last 5 years was 1.16 in the beginning of Covid-19 
pandemic. However, after the announcement of completion of the Brexit, GBP to 
USD has exceeded 1.35, reaching 1.36, the highest value in 2020. This also 
happened to several currencies, for example, GBP to CNY has climbed to 8.87. 
No material impact of 
Brexit for Pharma Business 
 
Source: Yahoo finance 
Since GSK has strong presence internationally, the exchange rate is one of the 
most important factors to affect its total revenue. For instance, there would be a 
growth in Consumer Healthcare Unit's turnover if eliminating the impact of 
exchange rate (-1% AER, 2% CER in 2018). In order to reduce the impact of 
foreign currency rate fluctuation on GSK’s total revenue, it has bought several 
financial derivatives, such as forward and swaps. Moreover, GSK seeks to 
denominate borrowings in the currencies of its principal assets and cash flows, that 
is USD, Sterling and EUR. Borrowings can be changed to other currencies as 
required. 
Forecast 
The main market of the GSK is in the US. The US segment has increased its 
contribution during the last 5 years. It accounted for 34% of the total revenue in 
2015 and climbed to 41% in 2019. Although the US market is the largest revenue 
origin of the firm, GSK has been seeking for opportunities in the worldwide, 
especially in the economies with high potential such as China, Japan and India. 
During last five years, it is notable that, GSK’s European segment CER10 growth 
rate has decreased constantly, reaching a negative point of -1% in 2018 while the 
international market (excluding USA and EU) has increased continuously from 1% 
to 6% (2016-2019) and strengthened its contribution to the total revenue. It reflects 
that GSK’s Europe market has been saturated while emerging markets such 
as Asia-Pacific still represent opportunities to explore. 
Covid-19 impacted GSK, particularly, in the Vaccines unit since the pandemic 
suspended regular immunization programs organized by The United Nations 
Children’s Fund (UNIFCEF), World Health Organization (WHO) and Pan American 
Health Organization (PAHO). In the meantime, the subdivision Established 
Pharmaceuticals of Pharmaceutical unit has also suffered in 2020 as most of their 
product’s patents expired and experienced fierce competition with its generic drugs 
substitution. Nevertheless, the Consumer Healthcare unit actually recorded very 
positive CER growth rate in first half year of 2020 comparing same period of 2019 
(Q1 2020: 46%; Q2 2020: 25%) although the growth rate plummeted to 2% in the 
Q3. The reason behind is that the joint-venture between GSK and Pfizer was 
completed in Q3 2019. Thus, FY19 Q3 Consumer Healthcare revenue had been a 
record (+ 25% CER), which set a high standard for FY20 Q3 to compare with. To 
be noted that the total revenue for first nine months of 2020 increased by 2%, 
reflecting that GSK remain resistant against Covid-19.  
In general, our revenue forecast model is based on historical income generated by 
each product. Each medicine or vaccine is forecasted, taking its past growth rate, 
 
10 The percentage that sales grew if exchange rates had been constant in the period. 
Source: Company Data 
the patent expiration date and its competitors patent expiration date (after the 
patents expiration, we assume the growth would be negative) into account. Our 
model is bult on following assumptions: Firstly, the total revenue from each 
medicine in 2020 is calculated by the average income of the first three quarters, 
multiplied by four11. Secondly, the patent expiration date for international market 
(excluding EU and USA) are the average of the expiration date of US and EU. 
Thirdly, after the patent expiration, the growth would be -10% in the first year, -
20% in the second year due to the fact that generic substitution drugs usually come 
out at second year of expiration, then, it will keep decreasing by -10% in the 
following years. These percentages (10%, 20%, 10%) are set to simulate the 
historical evolution of previous expired drugs. For instance, the Advair first 
experienced 12% decrease (around 10%) and 19% decrease (around 20%) in the 
second year after expiration and 16% for the third year. Another example could be 
Avodart which experienced a decreasing growth rate of 6%, 19% and 13%. Finally, 
if competitor drug’s patent expires before GSK’s corresponding drug, the sale of 
GSK’ drug will be negatively impacted as well since the genericization of its 
substitute will drag the price down. However, the indirect impact from generics of 
its competitor will be less than the direct impact of its own patent expiration. Thus, 
the growth rate is only assumed to decrease 10% every year. 
Pharmaceuticals 
Respiratory: GSK has been a global leader in respiratory for five decades, with 
the development of modern, innovative medicines for asthma and chronic 
obstructive pulmonary diseases. In the first nine months of 2020, respiratory sales 
were up 25% (CER growth rate of 26%) with significant growth from main drugs: 
Trelegy (accounts for 21% of total respiratory revenue), Relvar/Breo (31%) and 
Nucala (26%) in all regions. In US, based on the third quarter result, apart from 
continued growth of Trelegy (20% AER) and Nucala (25% AER). Relvar/Breo’s 
registered a growth of 64%, which is mainly resulted by the effect of a prior period 
RAR12 adjustment and a stronger US ICS/LABA13 market in the COVID-19 
pandemic environment. Moreover, the US FDA approved Trelegy Ellipta for 
asthma, becoming the first once-daily single inhaler triple therapy for the treatment 
of both asthma and COPD in the US. Furthermore, in 2019, Trelegy Ellipta was 
available in over 40 markets, including Japan and China, the two biggest 
economies in the Asia. 
In respiratory segment, as we mentioned previously, the three main products are 
Relvar/Breo Ellipta, Trelegy Ellipta and Nucala, whose patent expiration years 
 
11 4 refers to four quarters in a year.  
12 Returns and Rebate 
13 Inhaled corticosteroid and a long acting β2-agonist – maintenance treatment for asthma 
Source: Company Data 
Source: Analyst Graph 
Source: Analyst Graph 
are 2025/202614, 2027/2028 and 2027/2026 respectively. According to historical 
data, when GSK release a new drug, there would be a huge increase in revenue 
during the first two or three years, afterwards, it would drop dramatically until 
reaching a growth below 5% before expiration date. Taking the products 
competitors’ patent expiration date15 and the historical trend of a drug into 
consideration, it is assumed that these three products’ growth rate would decrease 
by 50% after 2020 until expiration year.  
In our forecast period, after 10 years, the main products did not change, Trelegy 
still has the highest sales in the respiratory segment in 2030, accounting for 39% 
of total revenue, even with the patent expiration. However, there are new drugs in 
developing, one of which has been in the third phase that is against COPD (the 
same indication as Advair). In our point of view, taking the continuously decrease 
of Advair into the consideration, this new medicine would substitute Advair to 
become a new “star” product in the respiratory segment. 
HIV: The HIV business is managed through ViiV Healthcare, a sole global 
specialist HIV pharmaceutical company, which is mostly owned by GSK (78% of 
equity) as we mentioned previously. There are 15 antiretroviral medicines in GSK’s 
portfolio and 12 products in the development pipeline. Apart from that, the EMAs 
Committee for Medicinal Products for Human Use published a positive opinion to 
recommend approval of Vocabria (cabotegravir injection) used in combination with 
Johnson & Johnson’s Rekambys (rilpivirine injection) for treatment of HIV.  
The total sales were £3.6bn, 0% AER, 1% CER during the first nine months of 
2020. The declines in Trivicay and Triumeq (the main products in HIV segment) 
were totally offset by the high growth of Juluca and Dovato (40% and >100% AER 
respectively). The decline of Triumeq is essentially resulted by the intensive 
competition of other successful HIV products (Descovy, Genvoya and Odefsey 
from Gilead16) and transition of the business to a new portfolio.  
Trivicay and Triumeq accounts for 86% of the HIV’s total revenue in 2019, 
while Juluca and Dovato only represent 9%. To forecast Trivicay and Triumeq’s 
future revenue, we maintain its growth of 2019 in the following years until their 
patent expiration date (both in 2027 US and in 2029 EU). Juluca is forecasted by 
the average growths of 2019 and 2020. Dovato, since it is a new drug, it is assumed 
100% of increase in 2021, then the growth would decrease by 50% per year util 
2027 in US and 2029 in EU. It is worth noting that, Juluca and Triumeq face same 
competitors. Juluca could increase its revenue during the last three years, while 
 
14 There are two patent expiration date, the first one refers the expiration date in US and second one refers in EU. 
15 Relvar’s main competitor: Symbicort (Patent expiration:2023); Trelegy: Trimbow (2030) and Nucala: Cinqair (2032), 
Dupixent (2034) 
16 The patent expiration for Descovy, Genvoya and Odefsey were 2022, 2029 and 2025, respectively. 
Source: Analyst Graph 
 
Source: Company Data 
 
Source: Analyst Graph 
triumeq’s sales declined.  
In this segment, due to the intensive competition face by Triumeq and same patent 
expiration date (2029) of its competitors, in the end of 2030, Trivicay has exceed 
Triumeq, to become the product with the highest sales. It represents 28% of HIV’s 
total revenue while Triumeq accounts for 24%. In our forecast model, the four 
medicines (Trivicay, Triumeq, Juluca and Dovato) that we mentioned previously 
would exceed £1bn of sales after 2023. 
Immuno-inflammation: Immuno-inflammation represents the medicines that are 
developed for immune-mediated diseases such as lupus and rheumatoid arthritis 
(RA). In nine months of 2020, it registered a sale of £521 million, with 18% growth 
rate (19% CER), while the main product - Benlysta, a first biologic therapy, 
registered a sale of £514 million. In 2019, Benlysta was approved in China and 
became the first biologic treatment to be approved in the US, EU and Japan.   
In US market, during last 5 years, Benlysta grows at 22% per year on average. 
However, in 2020, the growth, based on the average of the quarters, went to 9%. 
Since this medicine has no competitors17, it is assumed that it would increase at 
17% (average of the past growth rates including 2020) until its patent expiries 
(2025), afterwards, it would decrease by 10% in the first year, 20% in the second 
year and 30% in the third year. In EU market, the increase is bigger than US market 
(on average, 32% of increase per year before 2020). When including 2020 on the 
average, the growth falls to 27%. Moreover, in this market, the patent expiration 
begins in 2026. In international market, there are positive results from the pivotal 
BLISS-LN18 and the new product Duvroq launched in Japan in Q3 2020. Therefore, 
Benlysta is forecasted to grow with same pattern as in EU and US market, while 
Duvroq, since it is a new drug, we assumed that its first three years growths would 
be 100% then its growth rate would decrease by 50% in the following years.  
Before 2020, Benlysta is the only product in immuno-inflammation segment. Since 
it has no competitors, its growth rates are stable during the last 4 years. Benlysta 
would become blockbuster (Sales>£1bn) in 2023. In this segment, there are 6 
products in pipeline, three of which are in the third phase. Therefore, we expect 
that GSK will increase its products in Immuno-inflammation segment and gain 
more market share. 
Oncology: Oncology registered sales £257 million during the first nine months 
2020, with a growth rate of 57% (57% CER). Currently, GSK increases its 
investment in oncology assets such as Blenrep and ICOS, which reflecting the 
progression of GSK’s several key programs. 
 
17 Benlysta is the only biologic approved specifically for lupus and has moved slowly but surely toward blockbuster sales 
in the indication. 
18 Efficacy and Safety of Belimumab in Patients with Active Lupus Nephritis 
Source: Analyst Graph 
In US market, based on our first assumption, Zejula would increase by 51% in 
2020. We believe that 2021 will be a year recovering from Covid-19 but still 
suffering an afterpain. To balance the impact of Covid-19 on Zejula, its growth rate 
of 2021 would be the average of Q1 and Q2 2020 growths. The main reason is 
that Q1 2020 growth rate had not been impacted by Covid-19 while in Q2, it was 
highly affected. The growth rate would decrease by 50% until 2025 when its main 
competitor Lynparza’s (Astrazeneca PLC’s drug) patent expired. Afterwards, it 
decreases by 10% since Zejula’s patent only expired in 2030. Blenrep is a new 
drug in the oncology portfolio, therefore, it is assumed that its growths for the first 
4 years (2021-2024) are 100%, then decreased by 50%. The same pattern is 
applied in EU market. However, in this market, Zejula’s patent expiration year is in 
2028 and its competitor in 2029. Looking to International market, Zejula is 
introduced in 2020, which is also considered as a new drug in that market, 
therefore, it is assumed that its growth rate would be 100% until 2025 then 
decreased by 50% until 2027 when the Lynparza expired (2024 in China and 2029 
in Japan, average equal to 2027). Afterwards, it would decrease by 10% until 2029, 
when its patent expired. 
Established Pharmaceuticals: Established Pharmaceuticals segment includes 
the products without patent protection thus, it is highly impacted by generic 
competition. For instance, the generic albuterol substitutes on Ventolin and price 
pressure on Florent in US, the declining of Advair/Seretide sales and a lower sale 
of Viread in international market contribute to the decrease of sales for Established 
Pharmaceutical segment in a whole. Additionally, the government in some 
countries such as France and China promoted the use of generics. During the first 
nine months of 2020, sales were £5572 million, -16% AER, -14% CER.  
Majority of its products registers a negative growth rate, even in 2019 when there 
is no effect of Covid19 pandemic. To forecast this segment, we only rely on the 
growths of the last three years as the future growth of their revenues in US and EU 
markets. To be noted, in US market, the average of last three years of Ventolin is 
still positive (7%), however, taking Advair’s historical trend into the consideration, 
it is assumed its growth rate would decrease by 50% and it would be -10% after 
reaches 0%, and -20% in the following years. In international market, we maintain 
Ventolin’s growth rate (-10%) of 2020 to the following years. The main reason for 
keeping its growth is the positive results in the previous years (the growth rates are 
positives).  
Vaccines 
Vaccines business is highly impacted by the Covid-19 pandemic during the first 
nine months of 2020, registered sales of £4970 million, -8% AER, -7% CER. The 
Covid-19 results in the limited visits to healthcare practitioners and points of 
Source: Analyst Graph 
 
Source: Company Data, Analyst Graph 
vaccination, also the government stay-at-home directives directly affects the 
demand for vaccinees.  
There are two additional vaccines that GSK is developing: Respiratory Syncytial 
Virus (RSV) and Chronic Obstructive Pulmonary Diseases (COPD). These 
vaccines make GSK focus on therapeutic and antimicrobial resistance vaccines, 
which put GSK in a strong competitive position in the era of therapeutic vaccines. 
Currently, there is positive data from the Phase I/II for RSV vaccines. 
Meningitis: Meningitis segment develops vaccines for inflammation of the fluid 
and membranes surrounding the human brain and spinal cord. Bexsero, which 
already had a 70% share of the global meningitis B vaccines market in 2019, sales 
amounted to £755 million in the first nine months in 2020, with 7% AER, 5% CER. 
Due to the stable increase of Bexsero during the last 4 years, it is applied the 
average growth rates of these years as future growth rate until its patent expiration 
date (2027 in US and 2028 in EU). With these growths, it would exceed £1bn of 
sales in 2023. Another vaccine, Menveo, with a sale of 182 million, 9% AER and 
8% CER, expanded its market share in US market during the first nine months of 
2020. Taking this into consideration, and in order to exclude the effect of Covid19 
in this vaccine, FY19 growth rate is estimated as its future growth rate before the 
patent expiration (2025). In EU and international market, the growth rate would be 
the average 2019 and 2020. 
Influenza: The main product in the Influenza segment is Fluarix, this vaccine is 
highly welcome in US and International market (22% and 23% of increase in 2020, 
respectively). In the first nine months of 2020, it registered a sale of £481 million, 
with 19% growth rate (21% CER).  
In US and International markets, we maintain its growth rate of 2020 in the next 
year and a 50% of decrease in its future growth rate evolution after 2021 until 2026, 
when its patent expired. Note that in EU market, in order to include the effect of 
Covid-19, the growth for 2021 would be the average of the previous two years 
growths (2019 and 2020). 
Shingles: During the first nine months of 2020, the main product, Shingrix grew 
5% (6% CER) with a sale of £1344 million. This product contributes to 25% of the 
total Vaccine segment’ revenue in 2019. The main drivers for that increase are its 
strong performance in European market, especially in Germany, and the 
introduction of Shingrix in China. The negative growths in Q2 and Q3 2020 are 
resulted by the lower wellness visits and vaccination rates. Regarding forecast, 
with the appearance of new variant of the SARS-CoV-2 virus in UK, it is believed 
the impact of disease will continuously affect the economy in 2021. Therefore, in 
US market, if there is no impact of Covid-19, the growth would be 83% (Q1 2020), 
with impact of Covid19, the actual growth of 2020 is -8%. To forecast the growth 
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in 2021, a year still affected by Covid-19 but not as serious as 2020, 50% influence 
is applied in our model. That is, we combined these two situations and resulted 
38% (average method). Then the growth rate would decrease by 50% until 2026 
when the patent expires. To be noted that its main competitor Zostavax’s patent 
will be expired after 2030. Additionally, the U.S. Center for Disease Control has 
recommended Shingrix better than Zostavax since it is considered to be safer and 
more effective. In EU market, due to the huge increase of this vaccine in 2020 
(189%), the following years’ growth would decrease by 50% until its patent 
expiration year (2026). The same applies to international market.  
Established Vaccines: In this segment, due to lower demand and lower 
vaccination rate across all regions, most of established vaccines represents a 
negative growth rate except Priorix19 in the EU market and Cervarix20 in the 
international market. Infanrix, Boostrix and Hepatitis are the three main vaccines 
accounting for the largest revenue origin (52%) of Established Vaccine segments’ 
total revenue and registering a total sale of £1.24bn. These three vaccines are 
forecasted by the average of the FY18 and FY19 growth rates. The positive growth 
of Priorix is largely driven by the improvement of its supply in Europe market. Due 
to the patent expiration of this vaccine and the impact of Covid-19 in beginning of 
2021, in EU market, we use the average growth rates of 2019 and 2020 as the 
growth rate of 2021, then -50% on the growth rate in the following years. The 
Cervarix’s 2019 revenue has been highly impacted by the lower demand and 
competitive pressure in China. However, in 2020, there is huge increase in the 
international market (-75% in 2019 vs 272% in 2020), which is contradictory with 
its main competitor Gardasil (the patent expiration years are 2028 in US, 2021 in 
EU and 2017 in Japan), which is negatively impacted by Covid-19 (-26% AER, -
24% CER in 2020)21. This vaccine would be forecasted with same growth pattern 
as Priorix. While Priorix patent has been expired, Cervarix patent only expires in 
2028 in US and 2022 in EU. 
Consumer Healthcare 
Consumer Healthcare Unit had a sale growth of 19% AER, 23% CER, largely 
driven by the inclusion of Pfizer portfolio. In this unit, the past growth rates are 
always positive, except 2018 (-1%). Although it decreased 1% AER in 2018, it grew 
2% CER. The decrease is mainly resulted by increased competitive pressure in 
Europe and the divestment of some smaller brands, such as Horlicks and 
MaxiNutrition in UK. In the late stage, it also happens in India. 
 
19 Vaccine for the MMR (measles, mumps and rubella).  
20 Vaccine for human papilloma virus. 
21 Source: Quarterly report 2020 of Merck & Co, Inc. (Q2) 
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There are several drugs and medicines benefited from COVID-19 pandemic, for 
instance, Panadol in Pain relief area (31% growth rate, 34% CER) and Theraflu in 
Respiratory health area (14% growth rate, 16% CER). Furthermore, the increase 
of the awareness on the health and wellness by consumers also contributed to the 
sale growth of some Vitamins, minerals and supplements. In order to forecast the 
future revenue of this unit, it is used the average of the last 4 years’ growth. 
Afterwards, it would decrease by 50%. It is interesting to note that even in 
healthcare unit, EU market is reducing its contribution to the total revenue. For 
instance, in Q3 2019, EU market registered a sale of £1.8bn, £1.6bn of sales in 
US and the international market accounted for the largest revenue share (45%). In 
Q3 2020, US climbed to £2.5bn (52% of increase) while EU market’s revenue is 
£2bn (9% of increase). 
The inclusion of Pfizer’s portfolio increased the profit margin of Consumer 
Healthcare (C&H) Unit, however, in our point of view, with the increase of e-
commerce and entry of small and medium brand of C&H products in this market, 
there would not be huge growth in the future revenue.   
New Drugs  
We noticed that aside Advair, there will be very limited patents expired until 2027, 
while after that, GSK will face negative impact of expiration. Taking USA expiration 
date into consideration, by 2027, there will be 8 out of 19 patents expire. However, 
the new drug release, half of which is to be launched in 2026, will compensate the 
patent expiration issue. 
According to a research published by Informa, Amplion and the Biotechnology 
Innovation Organization (BIO)22, it takes 1 year from phase I to phase II with 
successful rate of 70%; 2 years from phase II to phase III and the success rate 
dropped to 33% and after 3 years clinical test of phase III with a success rate of 
58.1%, it still needs 2 years from submission to final approval. Additionally, we 
believed that some R&D resources were used to develop vaccines for Covid-19, 
therefore their planned R&D activities for existing pipelines were delayed for half 
year. In 2026, if the drugs are developed as we expect, GSK will have 11 out of 16 
medicines and vaccines to be lunched, offsetting the negative impact of original 
patent expiration challenge. It is estimated that there will be 4, 7, 4, 1 new products 
coming out respectively in 2023, 2026, 2028 and 2029. To simplify the complicated 
process of forecasting the probability for the new products, we choose a reference 
product for each segment with same indication to simulate their revenues and 
growth rates in the following years (For example: Oncology – Zejula – Cancer). 
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